469 related articles for article (PubMed ID: 37828829)
1. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Xie Z; Hu J; Gu H; Li M; Chen J
Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
6. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
7. [A new era for glucagon-like peptide-1 receptor agonists].
Neuville MF; Paquot N; Scheen AJ
Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
9. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
Suzuki T; Sato T; Tanaka M; Endo K; Nakata K; Ogawa T; Hosaka I; Akiyama Y; Umetsu A; Furuhashi M
J Diabetes Complications; 2024 Jul; 38(7):108779. PubMed ID: 38833854
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
[TBL] [Abstract][Full Text] [Related]
12. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
13. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Karagiannis T; Malandris K; Avgerinos I; Stamati A; Kakotrichi P; Liakos A; Vasilakou D; Kakaletsis N; Tsapas A; Bekiari E
Diabetologia; 2024 Jul; 67(7):1206-1222. PubMed ID: 38613667
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
Thethi TK; Pratley R; Meier JJ
Diabetes Obes Metab; 2020 Aug; 22(8):1263-1277. PubMed ID: 32267058
[TBL] [Abstract][Full Text] [Related]
17. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
19. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]